BIO Announces 2019 Start-up Stadium Winners
Annual competition takes place during BIO’s International Convention
Washington, DC – (July 1, 2019) – The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held last month at the BIO International Convention in Philadelphia. During five sessions over three days, live presentations of 50 finalists were evaluated by expert judges with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. One winner was chosen for each session. From 13 countries and 24 US states, competitors were judged on the strength of their commercially viable cutting-edge technologies and therapeutic solutions.
The winners are:
- EndObetes (New York) Session 1
- MNI, Inc. (Pennsylvania) Session 2
- ClostraBio, Inc. (Illinois) Session 3
- ChromaTan Corp. (Pennsylvania) Session 4
- Kaydence Pharma (Norway) Session 5
“The benefits of participating in the Start-up Stadium competition go beyond winning a contest,” said Nareg Sagherian, BIO’s Director of Investor Relations & Programming. “According to our surveys, even the companies that don’t win have been approached by investors who were either judges or audience participants listening to their presentation. These are opportunities that participating companies may not have had otherwise, and we are pleased with the enormous success of this interactive experience.”
Winning companies receive a one-year membership in BIO, a one-hour advisory discussion with two venture capital firms (Hemi Ventures and Wells Fargo Strategic Capital) and will be fast-tracked into the final selection phase for up to a $75,000 convertible note as part of the Delaware Innovation Space’s First Fund program.
A full list of 2019 participants and judges can be found here.